Want to see SE:XBRANE full AI Analyst Report?
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr5.42 - kr38.03
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
kr218.42M
Enterprise Valuekr232.63
Total Cash (Recent Filing)kr49.50M
Total Debt (Recent Filing)kr63.71M
Price to Earnings (P/E)0.9
Beta0.99
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-39.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.94
Revenue Forecast (FY)kr183.00M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a sizable equity base provide a durable financial buffer versus peers. Deleveraging from prior years reduces immediate refinancing risk and gives the company flexibility to fund development, partner deals or manufacturing investments without forcing near-term dilutive financing.
Diversified Biotech Business ModelA dual monetization strategy (partnering/milestones/royalties plus service revenues) creates multiple durable pathways to cash generation. This structure helps de-risk program economics, smooth revenue timing, and supports strategic flexibility when pursuing late‑stage development or commercial deals.
Meaningful Revenue Base With Recent GrowthHaving an established revenue base and recent positive TTM growth indicates market traction for services or partnered programs. That recurring top-line, even if variable, provides a foundation to scale margins if operating costs are controlled and supports longer-term partner negotiations or reinvestment choices.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow creates structural funding pressure. Continued cash burn forces reliance on external financing or asset sales, increasing dilution or leverage risk, and constrains the firm's ability to fund trials, scale manufacturing, or absorb setbacks without capital raises.
Weak And Deteriorating ProfitabilityPersistent operating losses and a slide in gross profit quality point to core margin and cost-structure weaknesses. Without sustained improvement, losses will erode equity and make long-term returns dependent on non-recurring items or successful commercialization, undermining durable financial health.
Revenue Volatility And Recent DeclinesMaterial year-to-year revenue swings reduce predictability for capacity planning and partner commitments. This structural volatility complicates forecasting, undermines negotiating leverage with partners, and makes long-term investment decisions riskier for both management and external stakeholders.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr5.42 and its highest was kr38.03 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr218.42M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Oct 30, 2026 which is in 102 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Jul 17, 2026. The company reported -kr0.554 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr0.554 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.935%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―